WEARING A MASK IS STILL REQUIRED IN PATIENT AREAS AT SUNNYBROOK. READ OUR VISITOR GUIDELINES »

Cancer trials
Hospital  >  Care Programs  >  Odette Cancer Program  >  Clinical trials

Trial details

Two Stereotactic MRI-Guided Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer

To find out more about this trial and your cancer treatment options, please speak with your doctor.

Trial short name: 2SMART

Official title: Two Stereotactic MRI-Guided Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer

Principal Investigator: Dr. Andrew Loblaw

Cancer type: Genitourinary
Cancer location: Genitourinary
Disease stage: Early Cancer
Trial phase:
Intervention:

Registration #:

Inclusion criteria: 1. Informed consent obtained 2. Men >18 years 3. Histologically confirmed prostate adenocarcinoma (centrally reviewed) 4. Favorable risk prostate cancer, defined as clinical stage T1-2c, Gleason Sum 7, and PSA 20 ng/mL (patients can have only one of T2c, Gleason Sum 7 and PSA 10-20 ng/ml) Exclusion criteria: 1. Androgen deprivation therapy (LHRH-agonists or antiandrogens) > 6 mo 2. Prior pelvic radiotherapy 3. Anticoagulation medication (if unsafe to discontinue for gold seed insertion) 4. Diagnosis of bleeding diathesis 5. Large prostate (>90cm3) on imaging 6. Immunosuppressive medications 7. Inflammatory bowel disease 8. Presence of a hip prosthesis